Cargando…

Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells

A family of monomodified bovine serum albumin (BSA) linked to methotrexate (MTX) through a variety of spacers was prepared. All analogues were found to be prodrugs having low MTX-inhibitory potencies toward dihydrofolate reductase in a cell-free system. The optimal conjugates regenerated their antip...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Itzik, Schnaider-Beeri, Michal, Fridkin, Mati, Shechter, Yoram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778984/
https://www.ncbi.nlm.nih.gov/pubmed/35056966
http://dx.doi.org/10.3390/pharmaceutics14010071
_version_ 1784637460516438016
author Cooper, Itzik
Schnaider-Beeri, Michal
Fridkin, Mati
Shechter, Yoram
author_facet Cooper, Itzik
Schnaider-Beeri, Michal
Fridkin, Mati
Shechter, Yoram
author_sort Cooper, Itzik
collection PubMed
description A family of monomodified bovine serum albumin (BSA) linked to methotrexate (MTX) through a variety of spacers was prepared. All analogues were found to be prodrugs having low MTX-inhibitory potencies toward dihydrofolate reductase in a cell-free system. The optimal conjugates regenerated their antiproliferative efficacies following entrance into cancerous glioma cell lines and were significantly superior to MTX in an insensitive glioma cell line. A BSA–MTX conjugate linked through a simple ethylene chain spacer, containing a single peptide bond located 8.7 Å distal to the protein back bone, and apart from the covalently linked MTX by about 12 Å, was most effective. The inclusion of an additional disulfide bond in the spacer neither enhanced nor reduced the killing potency of this analogue. Disrupting the native structure of the carrier protein in the conjugates significantly reduced their antiproliferative activity. In conclusion, we have engineered BSA–MTX prodrug analogues which undergo intracellular reactivation and facilitate antiproliferative activities following their entrance into glioma cells.
format Online
Article
Text
id pubmed-8778984
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87789842022-01-22 Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells Cooper, Itzik Schnaider-Beeri, Michal Fridkin, Mati Shechter, Yoram Pharmaceutics Article A family of monomodified bovine serum albumin (BSA) linked to methotrexate (MTX) through a variety of spacers was prepared. All analogues were found to be prodrugs having low MTX-inhibitory potencies toward dihydrofolate reductase in a cell-free system. The optimal conjugates regenerated their antiproliferative efficacies following entrance into cancerous glioma cell lines and were significantly superior to MTX in an insensitive glioma cell line. A BSA–MTX conjugate linked through a simple ethylene chain spacer, containing a single peptide bond located 8.7 Å distal to the protein back bone, and apart from the covalently linked MTX by about 12 Å, was most effective. The inclusion of an additional disulfide bond in the spacer neither enhanced nor reduced the killing potency of this analogue. Disrupting the native structure of the carrier protein in the conjugates significantly reduced their antiproliferative activity. In conclusion, we have engineered BSA–MTX prodrug analogues which undergo intracellular reactivation and facilitate antiproliferative activities following their entrance into glioma cells. MDPI 2021-12-28 /pmc/articles/PMC8778984/ /pubmed/35056966 http://dx.doi.org/10.3390/pharmaceutics14010071 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cooper, Itzik
Schnaider-Beeri, Michal
Fridkin, Mati
Shechter, Yoram
Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells
title Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells
title_full Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells
title_fullStr Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells
title_full_unstemmed Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells
title_short Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells
title_sort albumin–methotrexate prodrug analogues that undergo intracellular reactivation following entrance into cancerous glioma cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778984/
https://www.ncbi.nlm.nih.gov/pubmed/35056966
http://dx.doi.org/10.3390/pharmaceutics14010071
work_keys_str_mv AT cooperitzik albuminmethotrexateprodruganaloguesthatundergointracellularreactivationfollowingentranceintocancerousgliomacells
AT schnaiderbeerimichal albuminmethotrexateprodruganaloguesthatundergointracellularreactivationfollowingentranceintocancerousgliomacells
AT fridkinmati albuminmethotrexateprodruganaloguesthatundergointracellularreactivationfollowingentranceintocancerousgliomacells
AT shechteryoram albuminmethotrexateprodruganaloguesthatundergointracellularreactivationfollowingentranceintocancerousgliomacells